DAWN2 study results clarify greater need for psychosocial support and self-management education

The DAWN2TM study is an international investigation, initiated by Novo Nordisk and conducted in collaboration with International Diabetes Federation (IDF), the International Alliance of Patients' Organizations (IAPO) and the Steno Diabetes Center. The main objectives of DAWN2 include providing a better understanding and awareness of the potential impact that diabetes can have on the quality of life of people with diabetes and their family members. Further, the views of healthcare professionals on diabetes care and their insights for improvement of care delivery are explored.1

DAWN2 study, diabetes